Biopharma Credit PLC on Tuesday noted that investment firm Archimed will acquire Esperion Therapeutics.
Biopharma Credit, a London-based closed-ended investment company focused on life sciences industry, said the transaction is valued at up to about $1.1 billion in total equity value on a fully diluted basis, assuming full achievement of some commercial-based milestones.
Biopharma Credit said it alongside BioPharma Credit Investments V Master LP provided committed financing to Archimed of up to $400 million. Biopharma Credit’s allocation of such commitment will be between $78 million and $120 million, it said.
Biopharma Credit said Esperion expects the acquisition to close in the third quarter of 2026.
Biopharma Credit shares rose 0.7% to 70.01 pence each on Tuesday morning in London.
Copyright 2026 Alliance News Ltd. All Rights Reserved.